Emerging research elucidates key molecular pathways driving cancer progression and resistance. Studies reveal CX26 stabilizes oncogenic c-Myc in pancreatic cancer, enhancing tumor aggressiveness. Additionally, lactylation-mediated microRNA regulation contributes to therapy resistance, suggesting novel epigenetic intervention points. Investigations into SMARCA4 deficiency in thoracic tumors reveal molecular vulnerabilities that could be exploited therapeutically. These findings reveal the complex interplay of genetic and epigenetic modulators in cancer and underscore the potential of targeted therapies to improve patient outcomes.